SYRE
Spyre Therapeutics Inc.
NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY
$74.45
+3.56% today
Updated 2026-04-30
Market cap
$6.20B
P/E ratio
—
P/S ratio
650.22x
EPS (TTM)
$-1.98
Dividend yield
—
52W range
$12 – $75
Volume
1.1M
Spyre Therapeutics Inc. (SYRE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-25.20%
ROA
-19.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | — | $-10.35M | — | — | — |
| 2015 | $6.08M | $-11.29M | 98.54% | -185.95% | -185.62% |
| 2016 | $4.63M | $-21.70M | 100.00% | -473.34% | -468.84% |
| 2017 | $5.21M | $-27.24M | 100.00% | -531.72% | -523.27% |
| 2018 | $3.89M | $-44.35M | 100.00% | -1,169.32% | -1,140.64% |
| 2019 | $0.00 | $-78.25M | — | — | — |
| 2020 | $0.00 | $-80.89M | — | — | — |
| 2021 | $18.74M | $-65.80M | 100.00% | -350.33% | -351.14% |
| 2022 | $2.33M | $-83.81M | 100.00% | -3,640.23% | -3,598.75% |
| 2023 | $886000.00 | $-338.79M | -8.80% | -27,347.97% | -38,238.15% |
| 2024 | $886000.00 | $-208.02M | 100.00% | -23,540.18% | -23,478.33% |
| 2025 | $0.00 | $-155.20M | — | — | — |